Mohab M. Ibrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohab M. Ibrahim has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Laurent François Martin
Department of Pharmacology, Department of Anesthesiology, and Comprehensive Center for Pain and Addiction, College of Medicine, University of Arizona, Tucson, Arizona
9 shared publications Amol Patwardhan
Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, Arizona; Department of Anesthesiology, College of Medicine, The University of Arizona, Tucson, Arizona; Department of Neurosurgery, College of Medicine, The University of Arizona, Tucson, Arizona; Comprehensive Pain and Addiction Center, The University of Arizona, Tucson, Arizona
8 shared publicationsFrank Porreca
Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ. Bellampalli is now with the Mayo Clinic School of Medicine, Rochester, MN, United States
5 shared publications- Rajesh Khanna
University of Florida
5 shared publications Aubin Moutal
Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ. Bellampalli is now with the Mayo Clinic School of Medicine, Rochester, MN, United States
4 shared publications- Kevin Cheng
Department of Pharmacology, College of Medicine, the University of Arizona, Tucson, Arizona
4 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 11 (4) , e1463
Impact of chronic pain on the families of U.S. adults
Introduction: Chronic pain (CP) can profoundly strain family systems, yet few population studies have explored prevalence and population dynamics of CP with high impact on families. Objectives: Examining prevalence and phenomenological characteristics of chronic pain with high impact on the families of U.S. adults. Situating HICP-family within a tiered cascade of functional impact. Methods: Prevalence estimated using 2023 National Health Interview Survey Data (n = 29,522) Results: Findings are as follows: (1) the population prevalence of CP with high impact on families (high-impact chronic pain [HICP]-Family) is 4.4% among U.S. adults, 18.1% among U.S. adults with CP, and 46.3% among U.S. adults with HICP; (2) HICP-Family is almost exclusively reported by those who have HICP that limits their individual functioning in life and work, yet most of those with HICP do not report concomitant HICP-Family; (3) among U.S. adults reporting both HICP and HICP-Family, the prevalence of clinically significant anxiety/depression symptoms is 46.1%; (4) among all U.S. adults with clinically significant anxiety/depression symptoms, the prevalence of HICP and concomitant HICP-Family is 14.9%. Conclusion: The need to develop effective supports and promote adaptive resilience in families highly affected by CP is clear. Clinical tools to support person-centered assessment of family and relational functioning, development of effective family-level interventions for U.S. adults, and collaborative models of care are needed.
- 10 July 2026
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 11 (4) , e1463
Open AccessImpact of chronic pain on the families of U.S. adults
Introduction: Chronic pain (CP) can profoundly strain family systems, yet few population studies have explored prevalence and population dynamics of CP with high impact on families. Objectives: Examining prevalence and phenomenological characteristics of chronic pain with high impact on the families of U.S. adults. Situating HICP-family within a tiered cascade of functional impact. Methods: Prevalence estimated using 2023 National Health Interview Survey Data (n = 29,522) Results: Findings are as follows: (1) the population prevalence of CP with high impact on families (high-impact chronic pain [HICP]-Family) is 4.4% among U.S. adults, 18.1% among U.S. adults with CP, and 46.3% among U.S. adults with HICP; (2) HICP-Family is almost exclusively reported by those who have HICP that limits their individual functioning in life and work, yet most of those with HICP do not report concomitant HICP-Family; (3) among U.S. adults reporting both HICP and HICP-Family, the prevalence of clinically significant anxiety/depression symptoms is 46.1%; (4) among all U.S. adults with clinically significant anxiety/depression symptoms, the prevalence of HICP and concomitant HICP-Family is 14.9%. Conclusion: The need to develop effective supports and promote adaptive resilience in families highly affected by CP is clear. Clinical tools to support person-centered assessment of family and relational functioning, development of effective family-level interventions for U.S. adults, and collaborative models of care are needed.
- Open Access
- 26 September 2025
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 7 (1) , 1-9
“It’s legal, now what?” development, implementation, and evaluation of interdisciplinary cannabis education for healthcare trainees
Background: Healthcare professionals are motivated to improve their cannabis knowledge—yet few training opportunities exist. The unique legal status of cannabis, lack of rigorous research, and rapid expansion of consumer demand present challenges to the development and implementation of cannabis education for healthcare professionals and trainees. As a result, an alarming gap in quality of care is developing: health care professionals across disciplines lack the knowledge needed to counsel their patients, even as cannabis use rapidly accelerates. Methods: We aimed to address the gap by developing and implementing an interprofessional cannabis training for healthcare trainees. Considering the challenges to development and implementation of cannabis training, we identified 4 implementation strategies to maximize training quality, uptake, and utility: 1) incorporating a diverse array of scientific expertise and perspectives in curriculum development; 2) offering a comprehensive, evidence-based treatment of potential risks and potential benefits; 3) using an interprofessional training format; 4) adopting a person-centered lens with special emphasis on patient-provider communication. A post-survey evaluated implementation success and intermediate outcomes in trainee attitudes and behavioral intentions that would suggest high potential to deliver healthcare improvements at scale. Results: The virtual training “It's Legal, Now What? Cannabis Epidemiology, Treatment, and Safety Recommendations” was successfully implemented; since 2023 a total of 345 trainees in Pharmacy, Nursing, Public Health, and Medicine have earned certificates. Evaluation results are encouraging: 90% agree the training addressed a training need in their current role, 83% agree it should be required for trainees in their profession, 98% and 96% agree it comprehensively addressed potential risks and benefits, respectively, 94% agree it was inclusive of diverse perspectives, 94% agree it improved their knowledge of community resources, 96% report improved ability to respond to patients interested in cannabis, 96% report greater likelihood of providing information on cannabis to others, and 97% of trainees agree they learned information that would help them in their work or community. Conclusions: We present our training development process, implementation strategy, and evaluation as an adaptable model for contexts where both recreational and medical use of cannabis are legal.
- 26 September 2025
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 7 (1) , 1-9
Open Access“It’s legal, now what?” development, implementation, and evaluation of interdisciplinary cannabis education for healthcare trainees
Background: Healthcare professionals are motivated to improve their cannabis knowledge—yet few training opportunities exist. The unique legal status of cannabis, lack of rigorous research, and rapid expansion of consumer demand present challenges to the development and implementation of cannabis education for healthcare professionals and trainees. As a result, an alarming gap in quality of care is developing: health care professionals across disciplines lack the knowledge needed to counsel their patients, even as cannabis use rapidly accelerates. Methods: We aimed to address the gap by developing and implementing an interprofessional cannabis training for healthcare trainees. Considering the challenges to development and implementation of cannabis training, we identified 4 implementation strategies to maximize training quality, uptake, and utility: 1) incorporating a diverse array of scientific expertise and perspectives in curriculum development; 2) offering a comprehensive, evidence-based treatment of potential risks and potential benefits; 3) using an interprofessional training format; 4) adopting a person-centered lens with special emphasis on patient-provider communication. A post-survey evaluated implementation success and intermediate outcomes in trainee attitudes and behavioral intentions that would suggest high potential to deliver healthcare improvements at scale. Results: The virtual training “It's Legal, Now What? Cannabis Epidemiology, Treatment, and Safety Recommendations” was successfully implemented; since 2023 a total of 345 trainees in Pharmacy, Nursing, Public Health, and Medicine have earned certificates. Evaluation results are encouraging: 90% agree the training addressed a training need in their current role, 83% agree it should be required for trainees in their profession, 98% and 96% agree it comprehensively addressed potential risks and benefits, respectively, 94% agree it was inclusive of diverse perspectives, 94% agree it improved their knowledge of community resources, 96% report improved ability to respond to patients interested in cannabis, 96% report greater likelihood of providing information on cannabis to others, and 97% of trainees agree they learned information that would help them in their work or community. Conclusions: We present our training development process, implementation strategy, and evaluation as an adaptable model for contexts where both recreational and medical use of cannabis are legal.
- 28 March 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 217,p. e67821
Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management
Despite extensive research and the identification of numerous analgesic targets, the range of pharmacological treatments available for pain remains limited. However, a potential paradigm shift could introduce a new wave of non-pharmacological pain treatments with remarkable safety, efficacy, and tolerability. One promising area of investigation is photoneuromodulation using green light-emitting diodes (GLED, 525 nm), which have shown potential in alleviating pain in both acute and chronic conditions, leading to numerous preclinical and clinical studies exploring the efficacy of this therapy. These research projects have demonstrated how exposure to GLED enhances the activity of the endogenous opioid system in the brain and spinal cord after M-cone activation in the retina. The findings suggest that GLED may alleviate pain by modulating the descending pain pathway. In light of the compelling effects of GLED, the proliferation of photoneuromodulation investigations underscores the importance of establishing consistency in well-defined and standardized exposure protocols for preclinical and clinical trials. In preclinical studies, beneficial effects have been observed following a minimum of 2 days of exposure, with protocols involving 8 h of light at 100 lux during the 12 h light phase. In clinical trials, exposure protocols are tailored to the specific pathology under investigation. Exposure for 15 min has proven favorable in the modulation of acute post-surgical pain. For modulation of chronic pain, patients are instructed to use GLED at home for 1 to 2 h a day over 10 weeks. This article details preclinical and clinical protocols to improve reproducibility and consistency in the different studies evaluating photoneuromodulation benefits. By establishing these standardized protocols, this work aims to advance the clinical translation of GLED phototherapy as a viable non-pharmacological treatment for pain.
- 28 March 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 217,p. e67821
Optimizing Photoneuromodulation Techniques to Evaluate the Role of Green Light-Emitting Diodes in Pain Management
Despite extensive research and the identification of numerous analgesic targets, the range of pharmacological treatments available for pain remains limited. However, a potential paradigm shift could introduce a new wave of non-pharmacological pain treatments with remarkable safety, efficacy, and tolerability. One promising area of investigation is photoneuromodulation using green light-emitting diodes (GLED, 525 nm), which have shown potential in alleviating pain in both acute and chronic conditions, leading to numerous preclinical and clinical studies exploring the efficacy of this therapy. These research projects have demonstrated how exposure to GLED enhances the activity of the endogenous opioid system in the brain and spinal cord after M-cone activation in the retina. The findings suggest that GLED may alleviate pain by modulating the descending pain pathway. In light of the compelling effects of GLED, the proliferation of photoneuromodulation investigations underscores the importance of establishing consistency in well-defined and standardized exposure protocols for preclinical and clinical trials. In preclinical studies, beneficial effects have been observed following a minimum of 2 days of exposure, with protocols involving 8 h of light at 100 lux during the 12 h light phase. In clinical trials, exposure protocols are tailored to the specific pathology under investigation. Exposure for 15 min has proven favorable in the modulation of acute post-surgical pain. For modulation of chronic pain, patients are instructed to use GLED at home for 1 to 2 h a day over 10 weeks. This article details preclinical and clinical protocols to improve reproducibility and consistency in the different studies evaluating photoneuromodulation benefits. By establishing these standardized protocols, this work aims to advance the clinical translation of GLED phototherapy as a viable non-pharmacological treatment for pain.
- 28 March 2025
- Published by MyJove Corporation
- No. 217,p. e67821
JoVE Video Dataset
Despite extensive research and the identification of numerous analgesic targets, the range of pharmacological treatments available for pain remains limited. However, a potential paradigm shift could introduce a new wave of non-pharmacological pain treatments with remarkable safety, efficacy, and tolerability. One promising area of investigation is photoneuromodulation using green light-emitting diodes (GLED, 525 nm), which have shown potential in alleviating pain in both acute and chronic conditions, leading to numerous preclinical and clinical studies exploring the efficacy of this therapy. These research projects have demonstrated how exposure to GLED enhances the activity of the endogenous opioid system in the brain and spinal cord after M-cone activation in the retina. The findings suggest that GLED may alleviate pain by modulating the descending pain pathway. In light of the compelling effects of GLED, the proliferation of photoneuromodulation investigations underscores the importance of establishing consistency in well-defined and standardized exposure protocols for preclinical and clinical trials. In preclinical studies, beneficial effects have been observed following a minimum of 2 days of exposure, with protocols involving 8 h of light at 100 lux during the 12 h light phase. In clinical trials, exposure protocols are tailored to the specific pathology under investigation. Exposure for 15 min has proven favorable in the modulation of acute post-surgical pain. For modulation of chronic pain, patients are instructed to use GLED at home for 1 to 2 h a day over 10 weeks. This article details preclinical and clinical protocols to improve reproducibility and consistency in the different studies evaluating photoneuromodulation benefits. By establishing these standardized protocols, this work aims to advance the clinical translation of GLED phototherapy as a viable non-pharmacological treatment for pain.
- 28 March 2025
- Published by MyJove Corporation
- No. 217,p. e67821
JoVE Video Dataset
Despite extensive research and the identification of numerous analgesic targets, the range of pharmacological treatments available for pain remains limited. However, a potential paradigm shift could introduce a new wave of non-pharmacological pain treatments with remarkable safety, efficacy, and tolerability. One promising area of investigation is photoneuromodulation using green light-emitting diodes (GLED, 525 nm), which have shown potential in alleviating pain in both acute and chronic conditions, leading to numerous preclinical and clinical studies exploring the efficacy of this therapy. These research projects have demonstrated how exposure to GLED enhances the activity of the endogenous opioid system in the brain and spinal cord after M-cone activation in the retina. The findings suggest that GLED may alleviate pain by modulating the descending pain pathway. In light of the compelling effects of GLED, the proliferation of photoneuromodulation investigations underscores the importance of establishing consistency in well-defined and standardized exposure protocols for preclinical and clinical trials. In preclinical studies, beneficial effects have been observed following a minimum of 2 days of exposure, with protocols involving 8 h of light at 100 lux during the 12 h light phase. In clinical trials, exposure protocols are tailored to the specific pathology under investigation. Exposure for 15 min has proven favorable in the modulation of acute post-surgical pain. For modulation of chronic pain, patients are instructed to use GLED at home for 1 to 2 h a day over 10 weeks. This article details preclinical and clinical protocols to improve reproducibility and consistency in the different studies evaluating photoneuromodulation benefits. By establishing these standardized protocols, this work aims to advance the clinical translation of GLED phototherapy as a viable non-pharmacological treatment for pain.
- Open Access
- 30 July 2024
- Published by Wolters Kluwer Health in Pain
- Vol. 165 (12) , 2877-2887
The unmet mental health needs of U.S. adults living with chronic pain
Previous research suggests that individuals with mental health needs and chronic pain may be less likely to use mental health treatment compared with those with mental health needs only. Yet, few studies have investigated the existence of population-level differences in mental health treatment use. We analyzed data from the National Health Interview Survey (n = 31,997) to address this question. We found that chronic pain was associated with end-to-end disparities in the mental health journeys of U.S. adults: (1) Those living with chronic pain are overrepresented among U.S. adults with mental health needs; (2) among U.S. adults with mental health needs, those living with chronic pain had a lower prevalence of mental health treatment use; (3) among U.S. adults who used mental health treatment, those living with chronic pain had a higher prevalence of screening positive for unremitted anxiety or depression; (4) among U.S. adults living with both chronic pain and mental health needs, suboptimal mental health experiences were more common than otherwise—just 44.4% of those living with mental health needs and co-occurring chronic pain reported use of mental health treatment and screened negative for unremitted anxiety and depression, compared with 71.5% among those with mental health needs only. Overall, our results suggest that U.S. adults with chronic pain constitute an underrecognized majority of those living with unremitted anxiety/depression symptoms and that the U.S. healthcare system is not yet adequately equipped to educate, screen, navigate to care, and successfully address their unmet mental health needs.
- 30 July 2024
- Published by Wolters Kluwer Health in Pain
- Vol. 165 (12) , 2877-2887
Open AccessThe unmet mental health needs of U.S. adults living with chronic pain
Previous research suggests that individuals with mental health needs and chronic pain may be less likely to use mental health treatment compared with those with mental health needs only. Yet, few studies have investigated the existence of population-level differences in mental health treatment use. We analyzed data from the National Health Interview Survey (n = 31,997) to address this question. We found that chronic pain was associated with end-to-end disparities in the mental health journeys of U.S. adults: (1) Those living with chronic pain are overrepresented among U.S. adults with mental health needs; (2) among U.S. adults with mental health needs, those living with chronic pain had a lower prevalence of mental health treatment use; (3) among U.S. adults who used mental health treatment, those living with chronic pain had a higher prevalence of screening positive for unremitted anxiety or depression; (4) among U.S. adults living with both chronic pain and mental health needs, suboptimal mental health experiences were more common than otherwise—just 44.4% of those living with mental health needs and co-occurring chronic pain reported use of mental health treatment and screened negative for unremitted anxiety and depression, compared with 71.5% among those with mental health needs only. Overall, our results suggest that U.S. adults with chronic pain constitute an underrecognized majority of those living with unremitted anxiety/depression symptoms and that the U.S. healthcare system is not yet adequately equipped to educate, screen, navigate to care, and successfully address their unmet mental health needs.
- Open Access
- 1 September 2023
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 8 (5) , e1097
Increases in local skin temperature correlate with spontaneous foot lifting and heat hyperalgesia in both incisional inflammatory models of pain
Background: This study investigated if a localized increase in skin temperature in rat models of incisional and inflammatory pain correlates with the intensity of spontaneous and evoked pain behaviors. Methods: Anesthetized rats received either a 20-mm longitudinal incision made through the skin, fascia, and muscle of the plantar hind paw or an injection of complete Freund adjuvant into the plantar hind paw of anesthetized rats to induce local inflammation. Spontaneous and evoked pain behaviors were assessed, and changes in skin temperature were measured using a noncontact infrared thermometer. Results: There were no differences in skin temperature between the ipsilateral and contralateral hind paw before the incision or inflammation. Skin temperature increased at 2 hours after hind paw plantar incision or 1 day after inflammation of the affected paw, which gradually returned to baseline by the first day and fourth days after treatment, respectively. The increase in skin temperature correlated with the intensity of spontaneous pain behaviors and heat but not with mechanical allodynia. Conclusions: Our results suggest that a simple measurement of localized skin temperature using a noncontact infrared thermometer could measure the extent of spontaneous pain behaviors and heat hyperalgesia following plantar incision or inflammation in animals. In the absence of a reliable objective marker of pain, these results are encouraging. However, studies are warranted to validate our results using analgesics and pain-relieving interventions, such as nerve block on skin temperature changes.
- 1 September 2023
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 8 (5) , e1097
Open AccessIncreases in local skin temperature correlate with spontaneous foot lifting and heat hyperalgesia in both incisional inflammatory models of pain
Background: This study investigated if a localized increase in skin temperature in rat models of incisional and inflammatory pain correlates with the intensity of spontaneous and evoked pain behaviors. Methods: Anesthetized rats received either a 20-mm longitudinal incision made through the skin, fascia, and muscle of the plantar hind paw or an injection of complete Freund adjuvant into the plantar hind paw of anesthetized rats to induce local inflammation. Spontaneous and evoked pain behaviors were assessed, and changes in skin temperature were measured using a noncontact infrared thermometer. Results: There were no differences in skin temperature between the ipsilateral and contralateral hind paw before the incision or inflammation. Skin temperature increased at 2 hours after hind paw plantar incision or 1 day after inflammation of the affected paw, which gradually returned to baseline by the first day and fourth days after treatment, respectively. The increase in skin temperature correlated with the intensity of spontaneous pain behaviors and heat but not with mechanical allodynia. Conclusions: Our results suggest that a simple measurement of localized skin temperature using a noncontact infrared thermometer could measure the extent of spontaneous pain behaviors and heat hyperalgesia following plantar incision or inflammation in animals. In the absence of a reliable objective marker of pain, these results are encouraging. However, studies are warranted to validate our results using analgesics and pain-relieving interventions, such as nerve block on skin temperature changes.
- 23 October 2022
- Published by Elsevier in The Journal of Pain
- Vol. 24 (3) , 509-529
Green Light Exposure Elicits Anti-inflammation, Endogenous Opioid Release and Dampens Synaptic Potentiation to Relieve Post-surgical Pain
- 23 October 2022
- Published by Elsevier in The Journal of Pain
- Vol. 24 (3) , 509-529
Green Light Exposure Elicits Anti-inflammation, Endogenous Opioid Release and Dampens Synaptic Potentiation to Relieve Post-surgical Pain
- Open Access
- 20 September 2022
- Published by SAGE Publications in Clinical Medicine Insights: Case Reports
- Vol. 15
Case Report: Green Light Exposure Relieves Chronic Headache Pain in a Colorblind Patient
Patients with chronic headaches sometimes prefer non-pharmacological methods for pain management. We have shown previously that green light exposure (GLED, Green Light Emitting Diode) reversed thermal hyperalgesia and mechanical allodynia in a rat model of neuropathic pain. This effect is mediated through the visual system. Moreover, we recently showed that GLED was effective in decreasing the severity of headache pain and the number of headache-days per month in migraine patients. The visual system is comprised of image-forming and non-image-forming pathways; however, the contribution of different photosensitive cells to the effect of GLED is not yet known. Here, we report a 66-year-old man with headaches attributed to other disorders of homeostasis and color blindness who was recruited in the GLED study. The subject, diagnosed with protanomaly, cannot differentiate green, yellow, orange, and red colors. After completing the GLED exposure protocol, the subject noted significant decreases in headache pain intensity without reduction in the number of headache-days per month. The subject also reported improvement in the quality of his sleep. These findings suggest that green light therapy mediates the decrease of the headache pain intensity through non-image-forming intrinsically photosensitive retinal ganglion cells. However, the subject did not report a change in the frequency of his headaches, suggesting the involvement of cones in reduction of headache frequency by GLED. This is the first case reported of a colorblind man with chronic headache using GLED to manage his headache pain and may increase our understanding of the contribution of different photosensitive cells in mediating the pain-relieving effects of GLED.
- 20 September 2022
- Published by SAGE Publications in Clinical Medicine Insights: Case Reports
- Vol. 15
Open AccessCase Report: Green Light Exposure Relieves Chronic Headache Pain in a Colorblind Patient
Patients with chronic headaches sometimes prefer non-pharmacological methods for pain management. We have shown previously that green light exposure (GLED, Green Light Emitting Diode) reversed thermal hyperalgesia and mechanical allodynia in a rat model of neuropathic pain. This effect is mediated through the visual system. Moreover, we recently showed that GLED was effective in decreasing the severity of headache pain and the number of headache-days per month in migraine patients. The visual system is comprised of image-forming and non-image-forming pathways; however, the contribution of different photosensitive cells to the effect of GLED is not yet known. Here, we report a 66-year-old man with headaches attributed to other disorders of homeostasis and color blindness who was recruited in the GLED study. The subject, diagnosed with protanomaly, cannot differentiate green, yellow, orange, and red colors. After completing the GLED exposure protocol, the subject noted significant decreases in headache pain intensity without reduction in the number of headache-days per month. The subject also reported improvement in the quality of his sleep. These findings suggest that green light therapy mediates the decrease of the headache pain intensity through non-image-forming intrinsically photosensitive retinal ganglion cells. However, the subject did not report a change in the frequency of his headaches, suggesting the involvement of cones in reduction of headache frequency by GLED. This is the first case reported of a colorblind man with chronic headache using GLED to manage his headache pain and may increase our understanding of the contribution of different photosensitive cells in mediating the pain-relieving effects of GLED.
- 15 December 2021
- Published by Wolters Kluwer Health in Pain
- Vol. 163 (9) , 1751-1762
Conotoxin contulakin-G engages a neurotensin receptor 2/R-type calcium channel (Cav2.3) pathway to mediate spinal antinociception
Intrathecal application of contulakin-G (CGX), a conotoxin peptide and a neurotensin analogue, has been demonstrated to be safe and potentially analgesic in humans. However, the mechanism of action for CGX analgesia is unknown. We hypothesized that spinal application of CGX produces antinociception through activation of the presynaptic neurotensin receptor (NTSR)2. In this study, we assessed the mechanisms of CGX antinociception in rodent models of inflammatory and neuropathic pain. Intrathecal administration of CGX, dose dependently, inhibited thermal and mechanical hypersensitivities in rodents of both sexes. Pharmacological and clustered regularly interspaced short palindromic repeats/Cas9 editing of NTSR2 reversed CGX-induced antinociception without affecting morphine analgesia. Electrophysiological and gene editing approaches demonstrated that CGX inhibition was dependent on the R-type voltage-gated calcium channel (Cav2.3) in sensory neurons. Anatomical studies demonstrated coexpression of NTSR2 and Cav2.3 in dorsal root ganglion neurons. Finally, synaptic fractionation and slice electrophysiology recordings confirmed a predominantly presynaptic effect. Together, these data reveal a nonopioid pathway engaged by a human-tested drug to produce antinociception.
- 15 December 2021
- Published by Wolters Kluwer Health in Pain
- Vol. 163 (9) , 1751-1762
Conotoxin contulakin-G engages a neurotensin receptor 2/R-type calcium channel (Cav2.3) pathway to mediate spinal antinociception
Intrathecal application of contulakin-G (CGX), a conotoxin peptide and a neurotensin analogue, has been demonstrated to be safe and potentially analgesic in humans. However, the mechanism of action for CGX analgesia is unknown. We hypothesized that spinal application of CGX produces antinociception through activation of the presynaptic neurotensin receptor (NTSR)2. In this study, we assessed the mechanisms of CGX antinociception in rodent models of inflammatory and neuropathic pain. Intrathecal administration of CGX, dose dependently, inhibited thermal and mechanical hypersensitivities in rodents of both sexes. Pharmacological and clustered regularly interspaced short palindromic repeats/Cas9 editing of NTSR2 reversed CGX-induced antinociception without affecting morphine analgesia. Electrophysiological and gene editing approaches demonstrated that CGX inhibition was dependent on the R-type voltage-gated calcium channel (Cav2.3) in sensory neurons. Anatomical studies demonstrated coexpression of NTSR2 and Cav2.3 in dorsal root ganglion neurons. Finally, synaptic fractionation and slice electrophysiology recordings confirmed a predominantly presynaptic effect. Together, these data reveal a nonopioid pathway engaged by a human-tested drug to produce antinociception.
- 19 June 2021
- Published by Elsevier in The Journal of Pain
- Vol. 22 (12) , 1646-1656
Green Light Antinociceptive and Reversal of Thermal and Mechanical Hypersensitivity Effects Rely on Endogenous Opioid System Stimulation
- 19 June 2021
- Published by Elsevier in The Journal of Pain
- Vol. 22 (12) , 1646-1656
Green Light Antinociceptive and Reversal of Thermal and Mechanical Hypersensitivity Effects Rely on Endogenous Opioid System Stimulation